Australian researchers stopping melanoma in its tracks
11 September 2017
A team of Australian researchers has made the ultimate move in the battle to beat melanoma, successfully trialling a combination of new treatments to stop the disease in its tracks and prevent it from spreading or metastasising to distant organs.
Melanoma is the deadliest form of skin cancer, with one Australian dying from advanced melanoma every five hours.
Ground-breaking results from two international clinical trials conducted by investigators at Melanoma Institute Australia are being presented today at one of the world’s largest medical oncology conferences, the European Society for Medical Oncology (ESMO) 2017 Congress in Spain. The research has also been published in the prestigious New England Journal of Medicine today.
The trials, COMBI-AD and CheckMate 238, proved successful in preventing the spread of disease in Stage III melanoma patients whose tumours had been surgically removed. Until now, these patients were at a high risk (40−70 per cent) of their disease progressing to advanced and fatal melanoma.
“These results will change the way we treat melanoma patients as well as their quality of life,” says study author Professor Georgina Long (pictured), Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney.
“Until now, Stage III melanoma patients who have had their tumours surgically removed have simply had to play the waiting game, to see if their melanoma would metastasise or spread. Living with such fear severely affected them and their loved ones.
“Results from these clinical trials suggest we can stop the disease in its tracks – effectively preventing it from spreading and saving lives. Our ultimate goal of making melanoma a chronic rather than a terminal illness is now so much closer to being achieved,” she said.
In the COMBI-AD trial, patients were randomised to receive a combination of targeted therapies (dabrafenib and trametinib) or placebo for 12 months. Targeted therapies block the action of a particular gene which is a driver for melanoma. It was aimed at patients who are BRAF positive. It not only prevented resected Stage III melanoma from recurring, but it increased overall survival.
The CheckMate 238 trial involved patients with high risk Stage III and Stage IV disease who had had all melanoma surgically removed. They were randomised to be treated with the immunotherapy nivolumab or ipilimumab for 12 months. Immunotherapies reboot the immune system to attack the melanoma cells. Results showed nivolumab decreased the chance of relapse, and it had a superior safety profile over ipilimumab. This benefit was seen in patients regardless of BRAF mutation status. The follow up period is too short to yet determine long-term survival rates.
Research had already shown that targeted and immune therapies can successfully treat patients with advanced (Stage IV) melanoma that could not be removed surgically.
These clinical trials are the first in the world to give the treatments to melanoma patients at an earlier stage of the disease to prevent spread and recurrence.
“These clinical trials show we now have ammunition to prevent melanoma spreading and progressing, which until now was a critical area of disease behaviour where we had no control,” Professor Long said.
“This will change how melanoma is treated around the world, as we no longer have to passively wait to see if the melanoma spreads.
“We can now actively and effectively attack the melanoma at an earlier stage, reducing the dreadful anxiety for patients about progressing to a potentially terminal illness and ensuring they have much better outcomes,” she said.
History teacher and mother Renae Aslanis was a patient on the COMBI-AD trial. After having 10 lymph nodes removed, she decided to enter the clinical trial rather than just "watching and waiting". Now four-and-a-half years later, she is still "going strong"! Read more.
- Long G.V, et al. Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF-Mutated Melanoma. New England Journal of Medicine.
- Weber, J. et al. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.